Amir Shojaei

Company: AsclepiX Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Future Directions for Anti-VEGF Therapies 12:10 pm

Increasing patient response rates, not just prolonging treatment duration New therapy formats (bispecifics) – how does dual-specificity open up a wide range of therapeutic applications for these multifactorial diseases? Combinatorial approaches – approaches that could potentially be used on patients currently refractory or not optimally treated with anti-VEGF-A therapy aloneRead more

day: Day One